Add Yahoo as a preferred source to see more of our stories on Google. While AstraZeneca's gefurulimab met its primary and secondary endpoints in generalised myasthenia gravis (gMG) (Jack_the_sparow ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population of antibody-positive (including anti-AChR+a and ...

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ ...

Johnson & Johnson said a Phase 3 study of its treatment for the autoantibody disease generalized myasthenia gravis showed more than two years of improvements for patients. The pharmaceutical and ...

Johnson & Johnson (NYSE:JNJ) has reported new data from its Phase 3 Vivacity-MG3 trial showing that its therapy IMAAVY ...

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...

Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential ...

Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable ...

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that can cause muscle weakness, fatigue and problems ...

Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in ...